Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T16:43:53.603Z.
Calculation as of: 2026-10-06T16:43:53.603Z.
Quote observation: 2026-10-06T16:40:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Obsidian Therapeutics Inc.
Market Cap
$14.09M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| Obsidian Therapeutics Inc. (OBX) | $14.09M | N/A |
| Sintx Technologies, Inc. (SINT)vs › | $13.83M | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.79M | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $13.66M | N/A |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.57M | N/A |
| IN8bio, Inc. (INAB)vs › | $13.62M | N/A |
| Optimi Health Corp. (OPTH)vs › | $13.48M | N/A |
| Pasithea Therapeutics Corp. (KTTA)vs › | $14.97M | N/A |
| Passage Bio, Inc. (PASG)vs › | $13.11M | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.63M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
